New Insights Into the Use of Pls Across the Treatment Spectrum

Faculty:

Edwin DeJesus, MD, FACP W. David Hardy, MD Charles B. Hicks, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Summarize the findings from recent studies of PI-containing regimens in HIV-infected patients across the treatment spectrum
• Recount considerations that influence the choice between available PIs in treatment-naive patients, including efficacy, tolerability, and the consequences of virologic failure
• Discuss the evidence-based choice of a new PI in moderately treatment–experienced patients
• Describe the role of PIs in combination with other active agents, including novel antiretrovirals, when constructing new regimens for extensively pretreated patients